Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis

Journal of Investigative Dermatology

Volumn 133, Issue 7, 2013, Pages 1904-1907

  Navarini, Alexander A ^a   Valeyrie Allanore, Laurence ^b   Setta Kaffetzi, Niovi ^a   Barker, Jonathan N ^a,c   Capon, Francesca ^a   Creamer, Daniel ^d   Roujeau, Jean Claude ^b   Sekula, Peggy ^e   Simpson, Michael A ^a   Trembath, Richard C ^a   Mockenhaupt, Maja ^e   Smith, Catherine H ^a,c  

^a GUY S HOSPITAL   (United Kingdom)

^b HENRI MONDOR HOSPITAL   (France)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; NEOMYCIN; PENICILLIN DERIVATIVE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; CLINICAL FEATURE; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IL36RN GENE; LETTER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84879422419     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.44     Document Type: Letter

References (16)

1. Adzhubei IA, Schmidt S, Peshkin L et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248-9
2. Ameen M, Smith CH, Barker JN (2002) Pharmaco-genetics in clinical dermatology. Br J Derma-tol 146:2-6
3. ESP-NHLBI (2012) Exome Variant Server ohttp://evs.gs.washington.edu/EVS/ 4, Accessed 19 November 2012
4. Halevy S (2009) Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 9:322-8
5. Halevy S, Kardaun SH, Davidovici B et al. (2010) The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol 163:1245-52
6. Illing PT, Vivian JP, Dudek NL et al. (2012) Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486: 554-8
7. Marrakchi S, Guigue P, Renshaw BR et al. (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365:620-8
8. McCormack M, Alfirevic A, Bourgeois S et al. (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364:1134-43
9. Navarini AA, Kamacharova I, Kerl K et al. (2011) Ecthymatous skin eruption during therapy with cetuximab. Eur J Dermatol 21:282-3
10. Onoufriadis A, Simpson MA, Pink AE et al. (2011) Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 89:432-7
11. Pirmohamed M, Friedmann PS, Molokhia M et al. (2011) Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 89:896-901
12. Setta-Kaffetzi N, Navarini AA, Patel VM et al. (2013) Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypers. J Invest Dermatol 133:1366-9
13. Sidoroff A, Dunant A, Viboud C et al. (2007) Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 157:989-96 (Pubitemid 47583506)
14. Sidoroff A, Halevy S, Bavinck JN et al. (2001) Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 28:113-9 (Pubitemid 32112994)
15. Sulewski RJ Jr., Blyumin M, Kerdel FA (2008) Acute generalized exanthematous pustulosis due to clindamycin. Dermatol Online J 14:14
16. Whittam LR, Wakelin SH, Barker JN (2000) Generalized pustular psoriasis or drug-induced toxic pustuloderma? The use of patch testing. Clin Exp Dermatol 25:122-4 (Pubitemid 30212419)